Completed PHASE3 NCT00144846

Inhaled Albuterol Sulfate For Acute Wheezing Due To Obstructive Airways Disease In Children

A Randomized, Double-Blind, Parallel-group, Multi-Center Study of Albuterol Sulfate HFA Inhalation Aerosol Delivered Cumulatively With a Valved Holding Chamber and an Attached Facemask in Subjects Between Birth to 23 Months of Age With Acute Wheezing Due to Obstructive Airways Disease

Sponsor: GlaxoSmithKline

Conditions Asthma

Interventions albuterol sulfate inhalation aerosol

Updated 7 times since 2017 Last updated: Sep 22, 2016 Started: Sep 30, 2004 Primary completion: Feb 28, 2006 Completion: Feb 28, 2006

This PHASE3 trial investigates Asthma and is currently completed. GlaxoSmithKline leads this study, which shows 7 recorded versions since 2004 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Sep 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline

Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Alhambra, United States , Alliance, United States , Atlanta, United States , Boston, United States , Clearwater, United States , Columbus, United States , Dallas, United States , Dayton, United States , DeKalb, United States , Denver, United States and 19 more locations